HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bayouth, J. E. Articles by Fossella, F. V. Search for Related Content PubMed PubMed Citation Articles by Bayouth, J. E. Articles by Fossella, F. V.

Dosimetry and Toxicity of Samarium-153-EDTMP Administered for Bone Pain Due to Skeletal Metastases

Departments of Radiation Physics, Nuclear Medicine and Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas

Correspondence: For correspondence and reprints contact: John E. Bayouth, MS, The University of Texas M.D. Anderson Cancer Center, Dept. of Radiation Physics, Box 94, Houston, TX 77030.

ABSTRACT

Palliation of bone pain in patients with cancer metastatic to bone is being evaluated in several cancer centers by the administration of the bone-seeking phosphonate ethylenediaminetetra-methylenephosphonic acid (EDTMP) chelated with the beta particle-emitting radionuclide ¹⁵³Sm. Methods: In this study, ¹⁵³Sm-EDTMP was intravenously injected into 19 patients over a 1-min period. Patients received up to four injections of 18.5 MBq (0.5 mCi) or 37 MBq (1.0 mCi) per kilogram of body weight. Skeletal retention was calculated from urinary excretion. Results: No uptake of ¹⁵³Sm-EDTMP in nonskeletal tissues was observed in whole-body gamma camera images. The mean skeletal uptake for all patients was 54% ± 16% of the injected dose (%ID). This resulted in the bone marrow receiving 89 cGy/GBq ± 27 cGy/GBq (3.28 cGy/mCi ± 0.99 cGy/mCi), with calculated marrow doses ranging from 27 cGy to 338 cGy. For each patient, the estimated radiation absorbed dose to the marrow was correlated to the percent decrease in platelet number, ranging from 7.4% to 78.9%. Conclusion: Since the deviation of uptake between the four injections for a given patient (7.6% ID) was less than the deviation for all patients (16% ID), the initial dose may be used to estimate the skeletal uptake for the remaining doses. These radiation dose estimates permit patients at risk to be identified prior to reaching myelotoxicity and develop dose-response models. Thirteen patients (68%) reported significant pain relief from this radionuclide therapy. Bone pain appears to be alleviated by ¹⁵³Sm-EDTMP with limited red marrow doses and no toxic effects in other organs.

Key Words: bone marrow • ¹⁵³Sm-EDTMP toxicity • skeletal metastases • radionuclide therapy bone pain

This article has been cited by other articles:

				A. Goel, A. Dispenzieri, S. M. Geyer, S. Greiner, K.-W. Peng, and S. J. Russell Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma Blood, May 15, 2006; 107(10): 4063 - 4070. [Abstract] [Full Text] [PDF]

				S. C. Essman, M. R. Lewis, and W. H. Miller Intraorgan Biodistribution and Dosimetry of 153Sm-Ethylenediaminetetramethylene Phosphonate in Juvenile Rabbit Tibia: Implications for Targeted Radiotherapy of Osteosarcoma J. Nucl. Med., December 1, 2005; 46(12): 2076 - 2082. [Abstract] [Full Text] [PDF]

				P. M. Anderson, G. A. Wiseman, L. Erlandson, V. Rodriguez, B. Trotz, S. A. Dubansky, and K. Albritton Gemcitabine Radiosensitization after High-Dose Samarium for Osteoblastic Osteosarcoma Clin. Cancer Res., October 1, 2005; 11(19): 6895 - 6900. [Abstract] [Full Text] [PDF]

				H. Smith, A. Navani, and S. M. Fishman Radiopharmaceuticals for palliation of painful osseous metastases American Journal of Hospice and Palliative Medicine, July 1, 2004; 21(4): 303 - 313. [Abstract] [PDF]

				H. J. Siegel, J. V. Luck Jr, and M. E. Siegel Advances in Radionuclide Therapeutics in Orthopaedics J. Am. Acad. Ortho. Surg., January 1, 2004; 12(1): 55 - 64. [Abstract] [Full Text] [PDF]

				S. C. Essman, J. Lattimer, J. L. Cook, S. Turnquist, and K. Kuroki Effects of 153Sm-Ethylenediaminetetramethylene Phosphonate on Physeal and Articular Cartilage in Juvenile Rabbits J. Nucl. Med., September 1, 2003; 44(9): 1510 - 1515. [Abstract] [Full Text] [PDF]

				W. Brenner, W. U. Kampen, C. Brummer, C. von Forstner, M. Zuhayra, N. Czech, C. Muhle, and E. Henze Bone Uptake Studies in Rabbits Before and After High-Dose Treatment with 153Sm-EDTMP or 186Re-HEDP J. Nucl. Med., February 1, 2003; 44(2): 247 - 251. [Abstract] [Full Text] [PDF]

				J. G. Rajendran, J. F. Eary, W. Bensinger, L. D. Durack, C. Vernon, and A. Fritzberg High-Dose 166Ho-DOTMP in Myeloablative Treatment of Multiple Myeloma: Pharmacokinetics, Biodistribution, and Absorbed Dose Estimation J. Nucl. Med., October 1, 2002; 43(10): 1383 - 1390. [Abstract] [Full Text] [PDF]

				P. M. Anderson, G. A. Wiseman, A. Dispenzieri, C. A.S. Arndt, L. C. Hartmann, W. A. Smithson, B. P. Mullan, and O. S. Bruland High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients With Osteosarcoma and Bone Metastases J. Clin. Oncol., January 1, 2002; 20(1): 189 - 196. [Abstract] [Full Text] [PDF]

				W. Brenner, W. U. Kampen, C. v. Forstner, C. Brummer, M. Zuhayra, C. Muhle, N. Czech, and E. Henze High-Dose Treatment with 186Re-HEDP or 153Sm-EDTMP Combined with Amifostine in a Rabbit Model J. Nucl. Med., October 1, 2001; 42(10): 1545 - 1550. [Abstract] [Full Text] [PDF]

				A. N. Serafini Therapy of Metastatic Bone Pain J. Nucl. Med., June 1, 2001; 42(6): 895 - 906. [Abstract] [Full Text] [PDF]

				W. Brenner, W. U. Kampen, A. M. Kampen, and E. Henze Skeletal Uptake and Soft-Tissue Retention of 186Re-HEDP and 153Sm-EDTMP in Patients with Metastatic Bone Disease J. Nucl. Med., February 1, 2001; 42(2): 230 - 236. [Abstract] [Full Text]

				V. Rodriguez and D. Betcher 153Sm-EDTMP Journal of Pediatric Oncology Nursing, January 1, 1998; 15(2): 95 - 97. [PDF]

				A. D. AARON Current Concepts Review - Treatment of Metastatic Adenocarcinoma of the Pelvis and the Extremities J. Bone Joint Surg. Am., June 1, 1997; 79(6): 917 - 32. [Full Text]